MX367469B - Compuestos furanilo y su uso. - Google Patents

Compuestos furanilo y su uso.

Info

Publication number
MX367469B
MX367469B MX2015005883A MX2015005883A MX367469B MX 367469 B MX367469 B MX 367469B MX 2015005883 A MX2015005883 A MX 2015005883A MX 2015005883 A MX2015005883 A MX 2015005883A MX 367469 B MX367469 B MX 367469B
Authority
MX
Mexico
Prior art keywords
compounds
compounds provided
amelioration
prevention
treatment
Prior art date
Application number
MX2015005883A
Other languages
English (en)
Inventor
M Fung Leah
W H Chan Kyle
A Swindlehurst Cathy
Original Assignee
Novomedix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomedix Llc filed Critical Novomedix Llc
Publication of MX367469B publication Critical patent/MX367469B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

En la presente se proporcionan compuestos furanilo sustituidos que tienen la fórmula (I) (ver Fórmula) las composiciones farmacéuticas que contienen los compuestos, los métodos para su preparación y los métodos para su uso. Los compuestos que se proporcionan en la presente son útiles para el tratamiento, prevención y/o mejoría de diversos desórdenes, como el cáncer y los desórdenes proliferativos. En una modalidad, los compuestos que se proporcionan en la presente modulan la actividad de eIF4E. En una modalidad, los compuestos que se proporcionan en la presente modulan la actividad de la vía de Hedgehog. En una modalidad, los compuestos que se proporcionan en la presente se utilizan en combinación con cirugía, terapia de radiación, inmunoterapia y uno o más fármacos contra cáncer adicionales para el tratamiento, prevención y/o mejoría de cáncer y desórdenes proliferativos.
MX2015005883A 2010-06-07 2011-06-07 Compuestos furanilo y su uso. MX367469B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35230810P 2010-06-07 2010-06-07

Publications (1)

Publication Number Publication Date
MX367469B true MX367469B (es) 2019-08-23

Family

ID=44210539

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005883A MX367469B (es) 2010-06-07 2011-06-07 Compuestos furanilo y su uso.
MX2012014273A MX2012014273A (es) 2010-06-07 2011-06-07 Compuestos furanilo y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012014273A MX2012014273A (es) 2010-06-07 2011-06-07 Compuestos furanilo y su uso.

Country Status (11)

Country Link
US (3) US8722731B2 (es)
EP (1) EP2576532B1 (es)
JP (1) JP5855095B2 (es)
CN (2) CN104860907A (es)
AU (1) AU2011265047B2 (es)
CA (1) CA2801778C (es)
MX (2) MX367469B (es)
NZ (1) NZ604018A (es)
SG (1) SG186229A1 (es)
WO (1) WO2011156321A1 (es)
ZA (1) ZA201209237B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011265047B2 (en) 2010-06-07 2014-10-23 Novomedix, Llc Furanyl compounds and the use thereof
KR102137180B1 (ko) * 2012-09-21 2020-07-24 로드아일랜드하스피틀 암 치료를 위한 베타-하이드록실라제의 억제제
ES2689921T3 (es) 2012-11-30 2018-11-16 Novomedix, Llc Biarilsulfonamidas sustituidas y sus usos
CA2938592A1 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Methods for treating fibrotic disease
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
DE3933573A1 (de) 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5399564A (en) 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
HU219131B (hu) 1991-10-18 2001-02-28 Monsanto Co. Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
US5248221A (en) 1992-10-22 1993-09-28 Rohm And Haas Company Antifouling coating composition comprising lactone compounds, method for protecting aquatic structures, and articles protected against fouling organisms
US5259701A (en) 1992-10-22 1993-11-09 Rohm And Haas Company Antifouling coating composition comprising furan compounds, method for protecting aquatic structures, and articles protected against fouling organisms
US5334389A (en) 1992-10-15 1994-08-02 Duke University Antifouling coating and method for using same
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
TW304159B (es) 1993-08-24 1997-05-01 Janssen Pharmaceutica Nv
MY137123A (en) 1993-08-24 2008-12-31 Uniroyal Chem Co Inc Wood preservative oxathiazines
CN1065529C (zh) 1994-06-09 2001-05-09 爱斯制药株式会社 4－喹啉酮衍生物及其盐
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
EP1007012A4 (en) 1996-10-01 2006-01-18 Cima Labs Inc TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
WO1998028282A2 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
EP0957099B1 (en) 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
EP1028113A4 (en) 1998-08-04 2004-10-13 Toray Industries HETEROCYCLIC DERIVATIVES OF BENZENE IN FUSION AND THEIR USE
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6479531B1 (en) 1998-11-09 2002-11-12 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE60032483T2 (de) 1999-06-24 2007-04-19 Nihon Nohyaku Co., Ltd. Diamid-derivate von heterocyclischen dicarbonsäuren, insektizide für acker- und gartenbau und ein verfahren zu ihrer verwendung
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
GB0018758D0 (en) 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
WO2002028353A2 (en) 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1688412A3 (en) 2001-02-16 2006-08-16 Aventis Pharmaceuticals, Inc. Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
GB0117531D0 (en) 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003028641A2 (en) 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003064389A1 (fr) 2002-01-31 2003-08-07 Ono Pharmaceutical Co., Ltd. Composes bicycliques contenant de l'azote et medicaments contenant ces composes en tant qu'ingredient actif
DE60335099D1 (de) 2002-05-06 2011-01-05 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
PE20040574A1 (es) 2002-06-19 2004-09-08 Schering Corp Agonistas de los receptores cannabinoides
US7498349B2 (en) 2002-08-02 2009-03-03 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
WO2004087654A2 (en) 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
JP2004315511A (ja) 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
WO2004103960A2 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
US20040248972A1 (en) 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20050222408A1 (en) 2003-07-14 2005-10-06 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005013914A2 (en) 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP1668130A2 (en) * 2003-09-18 2006-06-14 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
WO2005033072A2 (en) 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
JP2005314347A (ja) 2004-04-30 2005-11-10 Japan Tobacco Inc 疼痛抑制剤
WO2005123089A2 (en) * 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
CA2571587C (en) 2004-06-25 2013-02-12 Janssen Pharmaceutica, N.V. Quaternary salt ccr2 antagonists
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20150090263A (ko) 2004-09-02 2015-08-05 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
RU2423351C2 (ru) 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
EP1869008A1 (en) 2005-04-11 2007-12-26 Probiodrug AG Inhibitors of prolyl endopeptidase
WO2007016292A2 (en) 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Heterocyclic amides as biofilm modulators
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
WO2007060140A2 (en) 2005-11-28 2007-05-31 F. Hoffmann-La Roche Ag Inhibitors of diacyglycerol acyltransferase (dgat)
KR20080087852A (ko) 2005-12-23 2008-10-01 아스트라제네카 아베 Ｇａｂａ-ｂ 수용체 조절제
EP2001868B1 (en) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
WO2007136703A1 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
RU2009120882A (ru) 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы
EA018441B1 (ru) * 2007-03-14 2013-08-30 ЭКСЕЛИКСИС ПАТЕНТ КОМПАНИ ЭлЭлСи Ингибиторы пути хеджхога
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
JP2010526850A (ja) * 2007-05-15 2010-08-05 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用な、新規な芳香族複素環式カルボン酸アミド誘導体
US8153644B2 (en) 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US20090099201A1 (en) 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US8093428B2 (en) 2007-10-26 2012-01-10 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
US8168829B2 (en) 2007-10-26 2012-05-01 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
WO2009057784A1 (ja) 2007-11-01 2009-05-07 Takeda Pharmaceutical Company Limited 複素環化合物
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
EP2264017A4 (en) 2008-04-04 2011-07-27 Takeda Pharmaceutical Heterocyclic derivative and its use
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
AU2011265047B2 (en) 2010-06-07 2014-10-23 Novomedix, Llc Furanyl compounds and the use thereof

Also Published As

Publication number Publication date
WO2011156321A1 (en) 2011-12-15
AU2011265047B2 (en) 2014-10-23
US9663483B2 (en) 2017-05-30
SG186229A1 (en) 2013-01-30
NZ604018A (en) 2015-02-27
MX2012014273A (es) 2013-03-22
US20140309297A1 (en) 2014-10-16
JP5855095B2 (ja) 2016-02-09
US9149527B2 (en) 2015-10-06
US20130116317A1 (en) 2013-05-09
CA2801778C (en) 2018-06-05
AU2011265047A1 (en) 2013-01-10
US8722731B2 (en) 2014-05-13
EP2576532A1 (en) 2013-04-10
EP2576532B1 (en) 2018-07-18
ZA201209237B (en) 2015-05-27
CN104860907A (zh) 2015-08-26
JP2013528215A (ja) 2013-07-08
WO2011156321A9 (en) 2012-04-05
US20160024040A1 (en) 2016-01-28
CN103108868A (zh) 2013-05-15
CA2801778A1 (en) 2011-12-15
CN103108868B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
EP4140487A8 (en) Combination therapy for treating cancer
WO2010110685A3 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
SG10201902664RA (en) Combination therapy for treating cancer
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2014100351A3 (en) 8'-hydroxy-dihydroergotamine compounds and compositions
WO2014160216A3 (en) Dual targeting anticancer agents
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
MX367469B (es) Compuestos furanilo y su uso.
UY33219A (es) Cetoenoles cíclicos para terapias
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018002932A (es) Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.
NZ719936A (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
MX370519B (es) Sulfonamidas con sustitucion biarilo y su uso.
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents